Flash Note: Annual Financial Results 2025
Posted at h
in Announcements
Flash Note: Annual Financial Results 2025 (Unaudited Financial Data) Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2%
Paiania, March 19, 2026 – Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025. Consolidated Sales from continuing operations, before Rebates & Clawbacks, amounted to Euro 70.03 million in 2025, compared to Euro 61.01 million during fiscal year 2024, reflecting an increase of 14.8%.